We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a downswing of 0.74%, while the tech-heavy Nasdaq depreciated by 0.03%.
Shares of the drugmaker have depreciated by 28.34% over the course of the past month, underperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2025. The company is predicted to post an EPS of $0.94, indicating a 44.62% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.88 billion, up 20.99% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.94 per share and a revenue of $50.41 billion, representing changes of +20.12% and +19.76%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.13% upward. Novo Nordisk is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Novo Nordisk has a Forward P/E ratio of 12.7 right now. This represents a discount compared to its industry average Forward P/E of 13.02.
It's also important to note that NVO currently trades at a PEG ratio of 0.97. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.12 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 60, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Novo Nordisk (NVO - Free Report) closed at $47.00, marking a -6.06% move from the previous day. This change lagged the S&P 500's 0.37% loss on the day. Elsewhere, the Dow saw a downswing of 0.74%, while the tech-heavy Nasdaq depreciated by 0.03%.
Shares of the drugmaker have depreciated by 28.34% over the course of the past month, underperforming the Medical sector's loss of 0.88%, and the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of Novo Nordisk in its forthcoming earnings report. The company is scheduled to release its earnings on August 6, 2025. The company is predicted to post an EPS of $0.94, indicating a 44.62% growth compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.88 billion, up 20.99% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.94 per share and a revenue of $50.41 billion, representing changes of +20.12% and +19.76%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Novo Nordisk. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.13% upward. Novo Nordisk is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Novo Nordisk has a Forward P/E ratio of 12.7 right now. This represents a discount compared to its industry average Forward P/E of 13.02.
It's also important to note that NVO currently trades at a PEG ratio of 0.97. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.12 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 60, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.